Immune reset is increasingly invoked to describe the possibility that a one-off intervention is able to produce durable treatment-free control of rheumatic autoimmune diseases. However, the term remains imprecise and is often conflated with lymphodepletion or immune reconstitution. We argue that immune reset should den...
Thomas Doerner, E. Schrezenmeier, Andrea R. Daamen et al.· Annals of the Rheumatic Dise...· 0 citations
Autoimmune diseases such as primary Sjögren’s disease (pSjD) and systemic lupus erythematosus (SLE) share clinical and serological features, including type I interferon signatures, autoantibody formation, and chronic inflammation, but the underlying immunopathology is not the same. To support the development of tar...
F. Szelinski, Ana-Luisa Stefanski, A. Wiedemann et al.· Frontiers in Immunology· 0 citations
The data suggest that increased type I IFN activity and IFN-associated signaling in T- and B-cell subsets are already present in anti-SSA–positive at-risk individuals, indicating progression from autoreactivity toward overt autoimmune disease.
J. Ritter, Ana-Luisa Stefanski, A. Aue et al.· Frontiers in Immunology· 0 citations
CD19 CAR T cells showed acceptable short-term tolerability in patients with treatment-refractory RA, justifying further evaluation, and the primary endpoint was met, allowing advancement to phase 2.
F. Albach, Marie C. Rehm, M. Hütter-Krönke et al.· Nature Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
